Expert consensus on the clinical application of ormutivimab injection for use against the rabies virus.

BACKGROUND There are no local or international guidelines or consensus on the use of mAbs against the rabies virus. RESEARCH DESIGN AND METHODS An expert group in the field of rabies prevention and control formulated the consensus presented in this paper. RESULTS Class III exposed persons of rabies exposed for the first time; Identify type II exposed persons with immune deficiency;those who are first exposed to Class II and re-exposed to Class III within 7 days.They can use olmtivir mAb injection after completing the PEP wound treatment.In the case of injection restrictions or a wound that is difficult to detect,it is recommended that the entire Ormutivimab dose be infiltrated close to the wound.For severe multi-wound bites, the recommended dosage of omtivir mAb is 20I U/kg.If the recommended dose cannot meet all of the wound infiltration requirements,appropriate dilution can be conducted at a dilution ratio of 3 ~ 5 times.If the requirements for infiltration cannot be met after dilution, it is recommended that the dosage be increased with caution (maximum dosage, 40 IU/kg).The use of Ormutivimab is safe and effective without any contraindications. CONCLUSIONS This consensus standardizes clinical use of Ormutivimab,improves post-exposure prophylaxis of rabies in China,reduces infection rate.

[1]  Todd G. Smith,et al.  A cocktail of human monoclonal antibodies broadly neutralizes North American rabies virus variants as a promising candidate for rabies post-exposure prophylaxis , 2022, Scientific Reports.

[2]  Rajesh K. Gupta,et al.  Monoclonal antibodies against rabies: current uses in prophylaxis and in therapy. , 2022, Current opinion in virology.

[3]  Jing-xin Li,et al.  Advances in the progress of monoclonal antibodies for rabies , 2022, Human vaccines & immunotherapeutics.

[4]  V. Suri,et al.  Measuring antibody titres following rabies postexposure prophylaxis in immunosuppressed patients: a norm rather than the exception , 2021, BMJ Case Reports.

[5]  P. Bookstaver,et al.  Administration of rabies immunoglobulin: Improving evidence‐based guidance for wound infiltration , 2021, Pharmacotherapy.

[6]  J. Linakis,et al.  Safety and efficacy of rabies immunoglobulin in pediatric patients with suspected exposure , 2021, Human vaccines & immunotherapeutics.

[7]  B. Bonfoh,et al.  RABIES IMMUNOGLOBULIN: BRIEF HISTORY AND RECENT EXPERIENCES IN CÔTE D'IVOIRE. , 2020, Acta tropica.

[8]  C. Rupprecht,et al.  Modern biologics for rabies prophylaxis and the elimination of human cases mediated by dogs , 2020, Expert opinion on biological therapy.

[9]  Hsin-Jung Li,et al.  Development of therapeutic antibodies for the treatment of diseases , 2020, Journal of Biomedical Science.

[10]  M. Kieny,et al.  Recent advances in the development of monoclonal antibodies for rabies post exposure prophylaxis: A review of the current status of the clinical development pipeline. , 2019, Vaccine.

[11]  K. O'Brien,et al.  The WHO position on rabies immunization – 2018 updates , 2019, Vaccine.

[12]  N. Gogtay,et al.  Comparison of a Novel Human Rabies Monoclonal Antibody to Human Rabies Immunoglobulin for Postexposure Prophylaxis: A Phase 2/3, Randomized, Single-Blind, Noninferiority, Controlled Study , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  C. Rupprecht,et al.  SYN023, a novel humanized monoclonal antibody cocktail, for post-exposure prophylaxis of rabies , 2017, PLoS neglected tropical diseases.

[14]  Jaykaran Charan,et al.  Monoclonal Antibodies: A Review. , 2017, Current clinical pharmacology.

[15]  E. R. Fernandes,et al.  Immunological aspects of rabies: a literature review , 2017, Archives of Virology.

[16]  H. Wilde,et al.  Injecting rabies immunoglobulin (RIG) into wounds only: A significant saving of lives and costly RIG , 2017, Human vaccines & immunotherapeutics.

[17]  S. Madhusudana,et al.  Local infiltration of rabies immunoglobulins without systemic intramuscular administration: An alternative cost effective approach for passive immunization against rabies , 2016, Human vaccines & immunotherapeutics.

[18]  T. Selhorst,et al.  Cross-neutralization of antibodies induced by vaccination with Purified Chick Embryo Cell Vaccine (PCECV) against different Lyssavirus species , 2014, Human vaccines & immunotherapeutics.

[19]  S. Sudarshan,et al.  Feasibility of reducing rabies immunoglobulin dosage for passive immunization against rabies: Results of In vitro and In vivo studies , 2013, Human vaccines & immunotherapeutics.

[20]  C. V. van Dolleweerd,et al.  Production, characterization, and antigen specificity of recombinant 62-71-3, a candidate monoclonal antibody for rabies prophylaxis in humans , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[21]  E. Kopel,et al.  Inadequate Antibody Response to Rabies Vaccine in Immunocompromised Patient , 2012, Emerging infectious diseases.

[22]  Mario Roederer,et al.  Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1 , 2010, Science.

[23]  N. Johnson,et al.  The immune response to rabies virus infection and vaccination. , 2010, Vaccine.

[24]  D. Teuwen,et al.  Rabies post-exposure prophylaxis with purified equine rabies immunoglobulin: one-year follow-up of patients with laboratory-confirmed category III rabies exposure in the Philippines. , 2009, Vaccine.

[25]  Thomas Müller,et al.  Development of a Mouse Monoclonal Antibody Cocktail for Post-exposure Rabies Prophylaxis in Humans , 2009, PLoS neglected tropical diseases.

[26]  B. Murphy,et al.  An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus , 2004, Nature Medicine.

[27]  C. Hanlon,et al.  Development of a cocktail of recombinant-expressed human rabies virus-neutralizing monoclonal antibodies for postexposure prophylaxis of rabies. , 2003, The Journal of infectious diseases.

[28]  S. Kästner,et al.  Automated plasmapheresis compared with other plasma collection methods in the horse. , 2003, Journal of veterinary medicine. A, Physiology, pathology, clinical medicine.

[29]  P. Casali,et al.  Biological characterization of human monoclonal antibodies to rabies virus , 1990, Journal of virology.

[30]  S L Morrison,et al.  Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[31]  G. Klein,et al.  Epstein-Barr virus susceptibility of normal human B lymphocyte populations , 1984, The Journal of experimental medicine.

[32]  H. Koprowski,et al.  Monoclonal antibodies against rabies virus produced by somatic cell hybridization: detection of antigenic variants. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[33]  H. Bourhy,et al.  [The use of passive rabies immunotherapy: from the past to the future]. , 2010, Biologie aujourd'hui.